- Home
- SIF vs SKYE Comparison
SIF vs SKYE Comparison
Compare SIF & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIF
- SKYE
- Stock Information
- Founded
- SIF 1913
- SKYE 2012
- Country
- SIF United States
- SKYE United States
- Employees
- SIF N/A
- SKYE N/A
- Industry
- SIF Office Equipment/Supplies/Services
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- SIF Industrials
- SKYE Health Care
- Exchange
- SIF Nasdaq
- SKYE Nasdaq
- Market Cap
- SIF 40.2M
- SKYE 44.9M
- IPO Year
- SIF N/A
- SKYE N/A
- Fundamental
- Price
- SIF $6.27
- SKYE $1.31
- Analyst Decision
- SIF
- SKYE Strong Buy
- Analyst Count
- SIF 0
- SKYE 5
- Target Price
- SIF N/A
- SKYE $14.75
- AVG Volume (30 Days)
- SIF 11.4K
- SKYE 314.8K
- Earning Date
- SIF 12-23-2025
- SKYE 11-10-2025
- Dividend Yield
- SIF N/A
- SKYE N/A
- EPS Growth
- SIF N/A
- SKYE N/A
- EPS
- SIF N/A
- SKYE N/A
- Revenue
- SIF $83,663,000.00
- SKYE N/A
- Revenue This Year
- SIF N/A
- SKYE N/A
- Revenue Next Year
- SIF N/A
- SKYE N/A
- P/E Ratio
- SIF N/A
- SKYE N/A
- Revenue Growth
- SIF 35.71
- SKYE N/A
- 52 Week Low
- SIF $2.33
- SKYE $1.14
- 52 Week High
- SIF $7.88
- SKYE $5.75
- Technical
- Relative Strength Index (RSI)
- SIF 43.64
- SKYE 38.04
- Support Level
- SIF $6.21
- SKYE $1.17
- Resistance Level
- SIF $6.58
- SKYE $1.46
- Average True Range (ATR)
- SIF 0.28
- SKYE 0.10
- MACD
- SIF -0.02
- SKYE 0.04
- Stochastic Oscillator
- SIF 41.57
- SKYE 30.25
About SIF SIFCO Industries Inc.
SIFCO Industries Inc is engaged in the production of forgings and machined components for the Aerospace and Energy, Defense and Commercial Space markets. Its processes and services include forging, heat-treating and machining. It serves original equipment manufacturers (OEM) as well as aftermarket customers. Its products are made of steel, stainless steel, titanium and aluminium and include OEM and aftermarket components for aircraft and industrial gas turbine engines, steam turbine blades, structural airframe components, aircraft landing gear components, aircraft wheels and brakes, critical rotating components for helicopters and industrial products. Substantial revenue is derived from North America as well as operates in Europe.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.